Get the Stockscreener App
57.27
1.20%
0.68
After Hours:
57.27
State Street Spdr S P Pharmaceuticals Etf stock is traded at $57.27, with a volume of 48,502.
It is up +1.20% in the last 24 hours and up +7.55% over the past month.
See More
Previous Close:
$56.59
Open:
$56.74
24h Volume:
48,502
Relative Volume:
0.51
Market Cap:
$229.97M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+4.93%
1M Performance:
+7.55%
6M Performance:
+20.90%
1Y Performance:
+49.73%
1-Day Range:
$56.74
$57.66
1-Week Range:
$55.19
$57.66
52-Week Range:
$37.31
$58.84
State Street Spdr S P Pharmaceuticals Etf Stock (XPH) Company Profile
Name
State Street Spdr S P Pharmaceuticals Etf
Sector
Industry
Phone
-
Address
-
Compare XPH vs VTI, SPY, IVV, VB, QQQ
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XPH
State Street Spdr S P Pharmaceuticals Etf
|
57.27 | 229.97M | 0 | 0 | 0 | 0.00 |
VTI
Vanguard Total Stock Market Etf
|
342.65 | 417.53B | 0 | 0 | 0 | 0.00 |
SPY
Spdr S P 500 Etf Trust
|
694.46 | 372.57B | 0 | 0 | 0 | 0.00 |
IVV
Ishares Core S P 500 Etf
|
697.69 | 253.41B | 0 | 0 | 0 | 0.00 |
VB
Vanguard Small Cap Etf
|
278.24 | 160.59B | 0 | 0 | 0 | 0.00 |
QQQ
Invesco Qqq Trust Series 1
|
628.60 | 124.43B | 0 | 0 | 0 | 0.00 |
State Street Spdr S P Pharmaceuticals Etf Stock (XPH) Latest News
Stock Market Research, Data and Tools - GuruFocus
Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a strong ETF right now? - MSN
SPDR Series TrustState Street SPDR S&P Pharmaceuticals ETF Reports Earnings Results for the Half Year Ended December 31, 2025 - marketscreener.com
XBI vs. IBB: The Biotech ETF Showdown That Analysts Say Has a Clear Winner in 2026 - 24/7 Wall St.
Stock Market Today: Dow, S&P 500 Futures Drop Ahead Of Trump's 'Power Plant Day' Deadline— UnitedHealth - Benzinga
State Street SPDR S&P Biotech ETF (XBI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Stock List: Research Stocks from Around the World - GuruFocus
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
The Trader: Biotechs Are a Healthy Growth Bet. Thank M&A and New Drugs. -- Barron's - 富途牛牛
This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It. - 24/7 Wall St.
Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now? - Yahoo Finance
Vanguard Global Government Bond (VGGF.AS) Holdings - Yahoo! Finance Canada
No deal yet? Trump readies new tariffs on select drugmakersreport (SPY:NYSEARCA) - Seeking Alpha
Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda - Benzinga
Top Pfizer Shareholders - Investopedia
Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs - Barron's
Biotech Stocks Are Up About 35% in the Past Year and Analysts Say the Biggest Gains Are Still Ahead - 24/7 Wall St.
Is State Street SPDR S&P Aerospace & Defense ETF (XAR) a Strong ETF Right Now? - Yahoo Finance
Should you invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)? - MSN
Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)? - Yahoo Finance
MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI’s 2026 Performance - 24/7 Wall St.
The 1-Minute Market Report, March 29, 2026 (NYSEARCA:SPY) - Seeking Alpha
KRE: Valuations Are Declining, But May Not Correct Soon (NYSEARCA:KRE) - Seeking Alpha
EU officials say Iran war raising risk of stagflation (SPY:NYSEARCA) - Seeking Alpha
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Investor Concerns Linger Amid Middle East Conflict - Moomoo
Chart Of The Day: What Will Oil Stocks Do If Oil Goes Vertical? - Seeking Alpha
SPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.0610 - MSN
XMHQ Struggles To Earn Market-Beating Returns, Consider Alternatives (NYSEARCA:XMHQ) - Seeking Alpha
Merck Preps for End of Keytruda Exclusivity with $6.7B Deal for Leukemia Treatment - The Daily Upside
ValuEngine Weekly Market Summary And Commentary - Seeking Alpha
IAK: Understanding The Structure And Suitability Of This Insurance ETF (NYSEARCA:IAK) - Seeking Alpha
Wall Street Lunch: Markets Seesaw After Trump’s Iran Pivot (undefined:SPY) - Seeking Alpha
Top performing semiconductor ETFs YTD, as sector rises on signals of war de-escalation (SMH:NASDAQ) - Seeking Alpha
Citi's large-cap stocks with negative ROE trends - Seeking Alpha
SA Asks: What can Congress do to protect Social Security benefits? - Seeking Alpha
SA Asks: What happens if the Social Security fund runs dry? - Seeking Alpha
Prestige Bets $1 Billion On World's Most Iconic Nasal Strip - Benzinga
Prestige Bets $1 Billion On World's Most Iconic Nasal Strip - Benzinga
Should State Street SPDR S&P 500 ETF Trust (SPY) Be on Your Investing Radar? - Yahoo Finance
Beyond Tech Industry: Here's how Biotech ETFs Are Riding the AI Wave - TradingView
Biotech ETF With A Twist: Defiance To Donate Initial Advisory Profits To Autism Causes - Benzinga
These 5 Undervalued ETFs Could Be Bargains Right Now - AOL.com
South Korea's $350B U.S. Investment Pledge: ETFs That Could Gain - TradingView
Most-traded sharesPage 568 - Capital.com
BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress - Benzinga
Should You Invest in the State Street SPDR S&P Retail ETF (XRT)? - Yahoo Finance
Is State Street SPDR S&P Oil & Gas Exploration & Production ETF (XOP) a Strong ETF Right Now? - Yahoo Finance
Better S&P 500 ETF: State Street's SPY vs. Vanguard's VOO - The Motley Fool
Most and least shorted healthcare stocks with up to $2B market cap in February - Seeking Alpha
Best S&P 500 ETFs to Buy in 2026 - The Motley Fool
How to Invest in SPDR S&P Biotech ETF (XBI) - The Motley Fool
State Street Spdr S P Pharmaceuticals Etf Stock (XPH) Financials Data
There is no financial data for State Street Spdr S P Pharmaceuticals Etf (XPH). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):